The 8 most recent market catalysts affecting $MYGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 55
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics filed an 8-K to affirm its fiscal year 2026 sales guidance. This means the company is not changing its previously communicated financial expectations for that perio…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6
UBS analyst Lu Li reiterated a 'Neutral' rating on Myriad Genetics but made a substantial cut to the price target, moving it from $6 down to $3.6. This action suggests that the ana…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 55
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Stephens & Co. analyst Mason Carrico maintained an 'Equal-Weight' rating on Myriad Genetics but lowered the price target from $5 to $3. This action indicates that while the analyst…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 95
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
This headline represents a major corporate catalyst for Myriad Genetics. The combination of missing current earnings expectations and significantly reducing future sales guidance s…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 95
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics experienced a substantial after-hours stock decline of 37.8% following its Q2 2026 earnings report. The company missed revenue expectations, reporting an 11% year-o…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 95
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
This headline represents a major negative corporate catalyst for Myriad Genetics. The combination of underperforming current results and a reduced future outlook signals deep-seate…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (MYGN) announced a substantial reduction in its FY2026 sales guidance, moving from an initial range of $860M-$880M down to $770M-$790M. This represents a $90M-$90M …
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate
This headline represents a significant negative corporate catalyst for Myriad Genetics (MYGN). The substantial miss on both adjusted EPS and sales estimates suggests underlying iss…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.